Gilead Acquires OM336 T-Cell Engager with $1.675bn Upfront, $500m Milestones
Gilead Sciences will acquire Ouro Medicines for $1.675bn upfront plus up to $500m in milestone payments to secure clinical-stage bispecific T-cell engager OM336. Galapagos NV will co-fund 50% of upfront and development costs through registrational trials, earning 20–23% royalties on net sales.
1. Acquisition Details
Gilead will acquire Ouro Medicines for $1.675bn upfront and up to $500m in milestone payments to secure OM336, a BCMA/CD3-targeting bispecific T-cell engager in clinical development for immune thrombocytopenia and autoimmune hemolytic anemia.
2. Co-development Terms
Under the agreement, Galapagos NV will fund 50% of the upfront payment and share development expenses through registrational studies, in exchange for 20–23% royalties on net sales outside Greater China.
3. Strategic Rationale
The transaction marks Gilead’s first entry into the T-cell engager space, diversifying its portfolio beyond HIV and complementing Kite’s autoimmune pipeline push.